THE ROLE OF IMMUNE RESPONSES IN THE PATHOGENESIS OF MYELODYSPLASTIC SYNDROMES.
Neanea, H., ElHalawani, N., Mourad, Z., Nafea, D., Suleiman, R. (2023). THE ROLE OF IMMUNE RESPONSES IN THE PATHOGENESIS OF MYELODYSPLASTIC SYNDROMES.. EKB Journal Management System, 5(1), 46-47. doi: 10.21608/alexpo.2023.200009.1588
Hashim Mohamed Neanea; Nabil Ahmed ElHalawani; Zeinab Ibrahim Mourad; Dalia Ahmad Nafea; Raitha Rashid Suleiman. "THE ROLE OF IMMUNE RESPONSES IN THE PATHOGENESIS OF MYELODYSPLASTIC SYNDROMES.". EKB Journal Management System, 5, 1, 2023, 46-47. doi: 10.21608/alexpo.2023.200009.1588
Neanea, H., ElHalawani, N., Mourad, Z., Nafea, D., Suleiman, R. (2023). 'THE ROLE OF IMMUNE RESPONSES IN THE PATHOGENESIS OF MYELODYSPLASTIC SYNDROMES.', EKB Journal Management System, 5(1), pp. 46-47. doi: 10.21608/alexpo.2023.200009.1588
Neanea, H., ElHalawani, N., Mourad, Z., Nafea, D., Suleiman, R. THE ROLE OF IMMUNE RESPONSES IN THE PATHOGENESIS OF MYELODYSPLASTIC SYNDROMES.. EKB Journal Management System, 2023; 5(1): 46-47. doi: 10.21608/alexpo.2023.200009.1588

THE ROLE OF IMMUNE RESPONSES IN THE PATHOGENESIS OF MYELODYSPLASTIC SYNDROMES.

ALEXMED ePosters
Article 1, Volume 5, Issue 1, January 2023, Page 46-47  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2023.200009.1588
View on SCiNiTO View on SCiNiTO
Authors
Hashim Mohamed Neanea1; Nabil Ahmed ElHalawani2; Zeinab Ibrahim Mourad3; Dalia Ahmad Nafea2; Raitha Rashid Suleiman email 4
1Department of Hematology, Alexandria University
2Department of Internal Medicine – Hematology Unit, Faculty of Medicine, Alexandria University
3Clinical pathology department, Alexandria Faculty of Medecine
4Department of Internal Medicine – Hematology Unit, Faculty of Medicine, Alexandria University
Abstract
Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis with blood cytopenias, morphological dysplasia and has tendency to progress into AML. MDS is regarded as the most prevalent form of acquired bone marrow failure syndrome in older adults > 65years of age and more common in men than in women. The current 2022 WHO classification introduces the term myelodysplastic neoplasms (abbreviated MDS) to replace myelodysplastic syndromes. The cause of MDS still remain unknown, however the etiology can be categorized into MDS arise without any underlying cause as de novo in older patients, or with underlying cause as secondary MDS.
The hallmark of MDS pathogenesis is dysregulated hematopoietic differentiation which result in impaired differentiation, morphological dysplasia, and cytopenia, and all of these are due to complex interplay between genetic and epigenetic alterations, bone marrow microenvironment, and the immune system. Therapeutic options for adult patients with MDS vary from supportive care to allo-HCT.
Keywords
Myelodysplastic syndromes (MDS); IMMUNE RESPONSES; bone marrow failure syndrome
Supplementary Files
Statistics
Article View: 37